This is a multi-center, randomized, double-blind, placebo-controlled, parallel group study of
two doses of CT1812 in adults with mild to moderate Alzheimer's Disease to evaluate the
safety and tolerability of oral CT1812, administered for 28 days. This trial may include up
to 8 qualified investigator sites in Australia.